April 2026 did not produce a broad rush of transactions across the United States. It produced a tighter cluster of deals around assets that take years to build, are difficult to replicate, or carry immediate strategic value. Building-products distribution, satellite infrastructure, and pharmaceutical portfolios dominated the month’s most consequential US-linked announcements.
The wider backdrop remained active, even if it was not calm. LSEG reported that first-quarter global M&A value rose above $1.2 trillion, with 22 deals worth more than $10 billion and cross-border activity up 47% year on year. Corroborating this, Dealogic put first-quarter announced deal value at $1.38 trillion, the second-highest first-quarter total on record. Banks entered April with fuller pipelines, while market volatility and geopolitical risk kept boards selective rather than expansive.
Healthcare supplied the busiest lane. Biotech M&A reached $84 billion in the first quarter, up from $44.4 billion a year earlier, as patent expiries, strong cash positions, and demand for pipeline depth pushed buyers forward. Elsewhere, industrial and infrastructure deals showed the same preference for durable positions — route density, installed networks, and assets that can absorb large capital commitments.
Five deals that defined April 2026 —
Building-products consolidation: QXO and TopBuild —
The month’s clearest industrial statement came on April 19, when Connecticut-based QXO agreed a $17 billion deal for Florida-based TopBuild. The combination will create the second-largest publicly traded building-products distributor in North America, with more than $18 billion in combined revenue. TopBuild shareholders were offered a cash-or-stock election at a 23.1% premium to the previous closing price.
QXO gains a broader position across roofing, insulation, repair, renovation, and commercial construction, including exposure to data-centre projects. The deal connects to a wider consolidation push in US building products as companies look to localise supply chains, manage tariff pressure, and secure stronger distribution footprints across end markets where execution still depends on physical presence.
Space infrastructure: Amazon and Globalstar —
On April 14, Amazon said it would acquire Globalstar in an $11.57 billion deal. The acquisition adds Globalstar’s two dozen satellites to Amazon’s network and strengthens its position in direct-to-device connectivity as it works towards a constellation of roughly 3,200 satellites by 2029.
The purchase expands Amazon’s reach in a market where spectrum, orbital assets, and launch timelines shape competitive distance. The deal will support direct-to-device services from 2028 and improve Amazon’s position against Starlink, even if launch capacity remains a constraint. Satellite infrastructure sat firmly inside April’s deal logic: control over scarce assets, long development cycles, and a clearer path into adjacent services.
Cross-border pharma scale: Sun Pharma and Organon —
April’s largest signed cross-border healthcare deal involving a US company arrived on April 26, when Sun Pharma agreed to buy New Jersey-based Organon in an all-cash transaction valued at about $11.75 billion including debt. It’s reportedly the largest overseas acquisition by an Indian pharmaceutical company, with Sun offering $14 per share.
Organon brings more than 70 medicines sold across about 140 countries, along with a stronger position in women’s health and biosimilars. The acquisition gives Sun broader commercial infrastructure in the US market and a larger specialty platform. It also reinforced a pattern visible across the month: overseas buyers still view US healthcare assets as scalable operating platforms with defensible revenue streams.
Buying scientific time: Eli Lilly and Kelonia —
On April 20, Eli Lilly agreed to buy Boston-based Kelonia Therapeutics for up to $7 billion, including $3.25 billion upfront and milestone payments. The deal gives Lilly access to experimental cancer therapies and strengthens an oncology strategy alongside its effort to reduce dependence on obesity medicines.
Kelonia specialises in in vivo CAR-T therapies, one of the more closely watched areas in cancer treatment. IQVIA noted that global spending on cancer medicines is projected to reach $409 billion by 2028. Lilly was not buying mature revenue. It was buying platform potential in a market where development timelines, scientific differentiation, and pipeline depth continue to shape valuation.
Paying for approved rarity: Neurocrine and Soleno —
On April 6, Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion in cash. This transaction gives Neurocrine access to Vykat XR, the first drug approved in the United States to treat hyperphagia associated with Prader-Willi syndrome. Soleno shareholders were offered $53 per share, a premium of about 34%.
The appeal was more immediate than early-stage platform science. Vykat XR generated about $190 million in sales in 2025 within roughly nine months of approval, while analysts projected more than $1 billion in annual sales by 2029. April’s healthcare deals repeatedly split into two camps: earlier-stage science with outsized platform potential, and approved or near-commercial assets that compress development risk.
The bottom line —
April’s buyers paid for positions with hard edges: distribution networks that are difficult to reproduce at scale, orbital infrastructure with long development cycles, and therapies with either scientific depth or approved demand. The month did not produce broad-based deal volume across every sector. It produced large commitments to assets with a clear route to growth, resilience, or strategic control.
Cross-border appetite remained visible, particularly in healthcare. Industrial buyers continued to pursue scale where physical networks still matter. The US regulatory environment remained more workable than many boards had expected at the start of the year, while financing windows were open enough to keep larger processes moving. That combination favoured buyers with balance-sheet flexibility and a sharply defined rationale. The month’s strongest deals were those that could be defended in operational terms from day one.
Four takeaways —
- Scarcity still commands a premium when it is operationally legible. Boards are paying for assets that solve a strategic problem quickly — route density, spectrum, commercial infrastructure, approved therapies, or platform science with obvious adjacency.
- Volatility, on its own, no longer stops activity. It narrows the field to transactions that can be defended in straightforward terms to investors, regulators, and employees.
- Healthcare buyers continue to use M&A to shorten timelines and add depth ahead of future revenue pressure, splitting capital between platform science and nearer-term commercial assets.
- Scale has returned as a persuasive deal thesis, but only where the operating case is simple enough to explain and robust enough to hold under scrutiny.
April did not mark a return to easy dealmaking in the United States. It showed where buyers were prepared to move at size: assets that extend a moat, strengthen infrastructure, or buy time in markets where delay carries its own cost.
You must be logged in to post a comment.